Pharmaceuticals & Therapeutics

As BD enters a new growth phase with interim leadership, the MedTech giant brings in Shawn Bevec, whose unique background bridges lab science and Wall Street.

In a major growth move, Franklin Street acquires hospitality leader Hodges Ward Elliott, creating a national CRE powerhouse with elite hotel brokerage expertise.

AstraZeneca's acquisition of Modella AI signals a major shift, embedding advanced AI directly into its cancer research to accelerate new treatments.

With new CEO Rebekah Gray at the helm, Gray Construction leverages its proven design-build model to tackle complex projects and power America's industrial resurgence.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

O Positiv's new menopause and metabolism products at Target signal a market shift. But how strong is the science behind these 'clinically studied' formulas?

A revolutionary bone graft that accelerates healing is now approved for more spinal surgeries, offering new hope to patients with chronic back pain.

For the third straight year, VIO Med Spa is the top franchise in its class. We explore the model driving its success in the booming wellness industry.

MedTech firm Lifeward is acquiring Oramed's oral insulin tech, despite a past trial failure, in a high-stakes deal that could redefine both companies.

The eyecare tech firm reports a strong fourth quarter fueled by its TearCare system, even as full-year results show a slight dip. Is this a turning point?

A new partnership aims to tackle the growing global health crisis of invasive fungal infections, a silent killer claiming millions of lives annually.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

Adimab's stellar 2025 reveals its crucial role as the hidden tech platform driving drug discovery for giants like Lilly and Regeneron.

Cosmetics brand Sorevna is diving into the crowded bath and body sector, promising a revolutionary launch. But can its science-first approach succeed?

Juvena Therapeutics lands a $33.5M Series B and a major pharma deal to advance its AI-discovered regenerative drugs for neuromuscular diseases.

Carlsmed's AI-driven aprevo® platform shows massive surgeon adoption and market growth, signaling a new era of personalized, cost-effective spine care.

A major new partnership is racing to deploy predictive tech, from blood tests to eye scans, to prevent millions of stillbirths in years, not decades.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.